# Garuda Therapeutics

**Canonical:** https://apis.io/providers/garuda-therapeutics/  
**APIs profiled:** 0

Garuda Therapeutics was a clinical-stage biotechnology company founded in 2021 by Sean Morrison and David Scadden and headquartered in Massachusetts (Cambridge, later Natick), developing off-the-shelf, self-renewing, HLA-compatible, transgene-free hematopoietic (blood) stem cell therapies intended to remove the dependency on a matched donor or on patient cells in the treatment of hematologic malignancies, sickle cell disease, beta-thalassemia and bone marrow failure. It raised roughly $184M across a $72M Series A and a $50M Series A-1 closed in March 2025, backed by OrbiMed Advisors, Northpond Ventures, Cormorant Asset Management and Kyowa Kirin. It is a therapeutics developer, not a software company: it never published an API, SDK, developer portal or machine-readable specification, and its website garudatx.com no longer serves company content and now resolves to a GoDaddy parking lander.

## Kin Score — 3.9 / 100 (minimal)

Scored 2026-08-17 under rubric 0.11.0.

| Facet | Score |
|---|---|
| Discoverability | 46.3 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Tags

Company, Biotechnology, Therapeutics, Cell Therapy, Stem Cells, Life Sciences, Healthcare, Defunct

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/garuda-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.